Call
+918447748545

Published on: Apr 06, 2020
2 minute read
By: Dr Rajan Choudhary

MicroRNA That Makes Them Fight COVID Better ?

Recently you may have read a New Delhi based International Center for Genetic Engineering and Biotechnology (ICGEB) sequenced the genome (genetic data) of SARS-COV-2 (coronavirus) from India, Italy, US, Nepal and Wuhan, China. They found that the Indian variant of SARS-CoV2 has the potential to be targeted by antiviral RNA within host cells, a feature that is unique to the Indian strain.

This amazing finding has been published on blogs, newspapers and other media as proof that Indians may not suffer as much as the rest of the world when the COVID-19 pandemic hits the country. One headline touted “MicroRNA in Indians may reduce severity of corona attack”, stating “Indians have comparatively better immunity compared to other countries”. Of course this article is being forwarded on WhatsApp, and enough people may take it as gospel. Is it true?

No.

If you want to know why, just look on the Journal’s website:

“these are preliminary reports that have not been peer-reviewed. They should NOT be regarded as conclusive, guide clinical practice/health-related behaviour, or be reported in news media as established information.”

Research is not easy. I could write a very long explanation for why, but I have summarised it below.

SUMMARY:

- To prove x causes y up to a high scientific standard is incredibly difficult

- Even if you think x causes y, someone might find a flaw in your study

- Numbers can be manipulated by statistics to show what you want to believe

- Reporters might not understand the study and mis-report it

- We all want to believe there is a magic cure that will protect us, that makes us special, immune to this disaster so we can get on with our lives. Unfortunately there simply isn’t one. And believing in them without fact checking can cause more harm than good.

IMMUNITY AGAINST COVID

So what about this study? Firstly it is looking at one tiny mechanism in a cell, when a cell can have millions of proteins responsible for a billion different functions in just the cell itself. Secondly it is not peer reviewed. This means no one has fact checked the study to check whether the design is valid, whether the statistics hold up, whether they have missed something or are making incorrect conclusions based off their data. Peer-reviewing a recent paper showing SARS-CoV-2 and HIV were extremely similar disproved this paper as false.

In the authors defence he acknowledges this:

“In our study, which is a purely computational one, we predicted that this microRNA binds to the SARS-Cov2 genome submitted from India. However, it is too early to comment on it because there is only one high coverage sequence from India, so far,”

Thirdly, the news article says that Indians have better immunity because of this “microRNA”. This is wrong. The study sequenced the genome of the virus, not of the Indian population. Antiviral microRNA is found in all people. The study simply suggests that this might be more effective at targeting the Indian strain of COVID, but it does not make any concrete claims that Indians are protected from COVID.

Again, the journal even states this:

“These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.”

But most importantly, even if the paper suggests that the Indian strain may be less potent, it does not give us an excuse to be reckless. We have to adhere to social distancing, hygiene, lockdown principles in order to prevent infection. Because what happens if you take the article stating “Indians have comparatively better immunity compared to other countries” as fact, use this as an excuse to go about your regular daily lives, and it actually turns out that the microRNA has little to no effect on COVID. This endangers yourself and those around you.

Be sensible. Listen to public health officials.

Dr Rajan Choudhary, UK, Chief Product Officer, Second Medic Inc

www.secondmedic.com

Read Blog

Digital Pharmacy Platforms India: How SecondMedic Is Transforming Medicine Access Through Technology

India’s healthcare system is rapidly digitizing, and one of the most impactful innovations is the rise of digital pharmacy platforms. These platforms make it easier for people to order medicines online, manage prescriptions, and access healthcare services without visiting a physical store.

As chronic diseases, online consultations, and digital health records become more common, digital pharmacy solutions are now a vital part of India's healthcare infrastructure. SecondMedic plays a key role in this evolution by providing secure, fast, and integrated digital pharmacy services.

What Are Digital Pharmacy Platforms?

Digital pharmacy platforms are online systems that allow users to:

Order prescription medicines
Upload or sync digital prescriptions
Schedule refills
Purchase OTC products
Track orders
Access pharmacist support

Instead of visiting a traditional pharmacy, users can manage medication needs from anywhere in India.

Why Digital Pharmacies Matter in India

India sees high demand for medicines due to:

Rising chronic diseases
Aging population
Urban mobility challenges
Increasing telemedicine adoption
Growing digital health awareness

Digital pharmacies bridge the gap between medical consultation and medication access.

Key Benefits of Digital Pharmacy Platforms

1. Convenience and Accessibility

Patients can order medicines anytime, especially helpful for elderly individuals or those living in remote areas.

2. Time and Cost Savings

Digital ordering eliminates long queues, multiple store visits, and pricing uncertainties.

3. Verified, Authentic Medicines

Reputed platforms ensure drugs come from licensed pharmacies with full batch traceability.

4. E-Prescription Integration

Digital prescriptions reduce manual errors and support seamless ordering.

5. Chronic Disease Medication Management

Automated refill reminders and scheduled deliveries help maintain treatment consistency.

6. Privacy and Discretion

Useful for sensitive medication categories where users may prefer confidential ordering.

The Growing Digital Pharmacy Market in India

According to Statista 2025:

The Indian e-pharmacy market is expected to reach USD 10 billion by 2027.
Nearly 35 percent of urban households now use digital pharmacy services.
Chronic disease patients are the largest user segment.

Government initiatives like ABDM also promote secure and standardized digital prescriptions.

SecondMedic’s Digital Pharmacy Ecosystem

SecondMedic integrates pharmacy services seamlessly within its broader digital health platform.

1. Online Medicine Ordering

Users can order medicines directly through the SecondMedic app or website.

2. E-Prescription Sync

Prescriptions from SecondMedic doctors sync automatically, reducing errors and delays.

3. Verified Inventory

All medicines are sourced from certified pharmacies with temperature-controlled storage and valid expiry cycles.

4. Chronic Care Refill System

For diabetes, hypertension, thyroid disorders, and cardiac conditions, patients can schedule monthly refills.

5. Real-Time Tracking

Users get live updates on order status, dispatch, and delivery.

6. Secure Payment Gateway

Digital payments are supported through encrypted channels, ensuring safety and transparency.

7. Integration with Medical Consultations

After virtual consultations, prescribed medicines can be ordered instantly on the same platform.

How Digital Pharmacy Platforms Support Telemedicine

Telemedicine has become a cornerstone of modern healthcare. Digital pharmacies complement this by:

Enabling immediate access to prescribed medicines
Ensuring continuity of care
Reducing patient dependency on physical pharmacies
Streamlining doctor-to-pharmacy communication

Together, they create an efficient, patient-centered care loop.

Challenges in India’s Pharmacy System and How Digital Platforms Solve Them

1. Fragmented Pharmaceutical Distribution

Digital systems bring transparency and accountability.

2. Prescription Mismanagement

E-prescriptions minimize errors and duplication.

3. Limited Accessibility in Rural Areas

Digital ordering delivers medicines directly to underserved regions.

4. Inconsistent Medicine Availability

Real-time inventory ensures availability and alternatives.

5. Lack of Patient Awareness

Digital platforms offer information on dosage, interactions, and side effects.

Regulatory Framework for Digital Pharmacies in India

To ensure safety and compliance, digital pharmacies follow:

Drugs and Cosmetics Act (1940)
Pharmacy Practice Regulations
ABDM standards for digital prescriptions
DPDP Act for data security
CDSCO guidelines for online pharmacies

SecondMedic maintains full compliance with regulatory requirements.

Future of Digital Pharmacy in India

The sector is expected to grow due to:

AI-based medicine recommendations
Smart refill systems
Blockchain for supply chain verification
Automated pharmacy logistics
Drone-based delivery pilots in some states

SecondMedic is actively building tools to support next-generation pharmacy automation and integrated digital care.

Why Patients Trust SecondMedic’s Pharmacy System

Authentic and verified medicines
Transparent pricing and secure payments
Direct connection with healthcare consultations
Support for chronic care medication
Nationwide delivery capability
User-friendly ordering process
Compliance with all digital health safety standards

SecondMedic brings reliability, convenience, and safety under one unified digital healthcare platform.

Conclusion

Digital pharmacy platforms are redefining how India accesses medicines. They improve convenience, enhance safety, support telemedicine, and empower patients to manage chronic conditions more effectively. SecondMedic’s digital pharmacy provides an integrated solution that combines e-prescriptions, secure ordering, and nationwide delivery to simplify healthcare access.

To order medicines or explore digital pharmacy services, visit www.secondmedic.com

References

Statista – India E-Pharmacy Market Outlook 2025
IMARC Group – Digital Healthcare Market India 2025
NITI Aayog – Digital Health Tech Landscape 2024
ABDM – Digital Prescription Guidelines
FICCI – Healthcare Innovation Report 2024

Request A Callback

+91

By using this website/app, I confirm that I am at least 18 years old and consent to the processing of my personal data in accordance with the Terms of Service, Privacy Policy, and Declaration.